Toward reducing immunogenicity of enzyme replacement therapy: altering the specificity of human β-glucuronidase to compensate for α-iduronidase deficiency
Open Access
- 28 August 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 28 (11) , 519-530
Abstract
Enzyme replacement therapy (ERT) is an effective treatment for many patients with lysosomal storage disorders caused by deficiency in enzymes involved in cell metabolism. However, immune responses that develop against the administered enzyme in some patients can hinder therapeutic efficacy and cause serious side effects. Here we investigated the feasibility of a general approach to decrease ERT immunogenicity by altering the specificity of a normal endogenous enzyme to compensate for a defective enzyme. We sought to identify human β-glucuronidase variants that display α-iduronidase activity, which is defective in mucopolysaccharidosis (MPS) type I patients. A human β-glucuronidase library was screened by the Enzyme Cleavable Surface-Tethered All-purpose Screen sYstem to isolate variants that exhibited 100–290-fold greater activity against the α-iduronidase substrate 4-methylumbelliferyl α-l-iduronide and 7900–24 500-fold enzymatic specificity shift when compared with wild-type β-glucuronidase. In vitro treatment of MPS I cells with the β-glucuronidase variants significantly restored lysosome appearance similar to treatment with α-iduronidase. Our study suggests that β-glucuronidase variants can be isolated to display α-iduronidase activity and produce significant phenotype improvement of MPS I cells. This strategy may represent a possible approach to produce enzymes that display therapeutic benefits with potentially less immunogenicity.Keywords
Funding Information
- Ministry of Science and Technology, Taipei, Taiwan
This publication has 49 references indexed in Scilit:
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cellsScience, 2015
- Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERTPLOS ONE, 2013
- Structure‐based redesign of proteins for minimal T‐cell epitope contentJournal of Computational Chemistry, 2013
- ECSTASY, an adjustable membrane-tethered/soluble protein expression system for the directed evolution of mammalian proteinsProtein Engineering, Design and Selection, 2012
- Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cellsMolecular Genetics and Metabolism, 2012
- Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral driftProceedings of the National Academy of Sciences, 2011
- Directed Evolution of a Lysosomal Enzyme with Enhanced Activity at Neutral pH by Mammalian Cell-Surface DisplayChemistry & Biology, 2008
- Membrane-localized activation of glucuronide prodrugs by β-glucuronidase enzymesCancer Gene Therapy, 2006
- Signal for Attachment of a Phospholipid Membrane Anchor in Decay Accelerating FactorScience, 1987
- Functions of LysosomesAnnual Review of Physiology, 1966